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Abstract
Alpha-toxigenic Clostridium septicum (CS), the cause of turkey cellulitis, results in
devastating mortality with high costs for the industry. Various vaccinations have been evaluated
to prevent this disease with moderate success. Ability of a CS bacterin-toxoid, in conjunction
with adjuvants such as aluminum hydroxide, mannoslyated chitosan, or a water-in-oil Seppic
Montanide 71 R VG adjuvant (OE) to induce immunity was evaluated in a 7-week study
(Experiment 1). Poults (20/group) were vaccinated day-of-hatch, boosted at 5 weeks-of-age and
compared to unvaccinated controls. Antibody levels were determined by ELISA for all
experiments. In experiment 1, initial vaccination with the OE resulted in significantly (P<0.05)
higher antibody levels at 5 weeks-of-age, and at 7 weeks-of-age OE resulted in numerically
increased antibody levels compared to all vaccinated groups. Efficacy of the OE vaccine was
then evaluated in two field trials (Experiment 2 and 3) with treatments including a nonvaccinated control group and a vaccinated group. Non-vaccinates were marked by removal of the
dewclaw at the hatchery and comingled during growout (Experiment 2 and 3). Experiment 2
consisted of 3 houses: House 1 (HS1), House 2 (HS2), and House 3 (HS3). Mortality associated
with cellulitis was recorded once the first case was observed. Blood samples were obtained at 8,
12, and 16 weeks-of-age. Antibody levels (S/P ratio) in vaccinated groups for weeks 12 and 16
were significantly higher (P<0.05) than the control groups for all 3 houses. In HS1 and HS2, low
CS-associated mortality was observed and there was no significant difference in mortality/total
(%) between control and vaccinated group. In HS3, control mortality/total (%) was significantly
(P<0.001) higher than mortality in vaccinated turkeys. Experiment 3 consisted of 6 farms with 14 houses/farm. Vaccination significantly (P<0.05) reduced CS-related mortalities as compared to
controls in 5 of 6 farms in experiment 3 and antibody titers were significantly (P<0.05) higher in
vaccinated turkeys at 12 and 16 weeks for all 6 farms. Based on these results, W/O emulsion

vaccines, such as this alpha-toxin bacterin-toxiod with Montanide 71 R VG adjuvant, can be
used to increase antibody titers and may reduce related mortalities in the field.
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Chapter I. Introduction
Turkey cellulitis, also referred to as clostridial dermatitis, is a problematic disease with
prevalence escalating over the last two decades in the United States (Lighty et al., 2016). Peak
incidence occurs in turkey flocks around 13-18 weeks-of-age (Clark et al., 2010). Clostridium
perfringens and Clostridium septicum are opportunistic pathogens that have been isolated from
cellulitis lesions (Thachil et al., 2010), however, C. septicum has been identified as the primary
etiology responsible for cellulitis in commercial turkeys (Tellez et al., 2009). Controlling C.
septicum is difficult due to the probability of the pathogen being a commensal organism within
the gastrointestinal tract of healthy animals (Clark et al., 2010). The spores can also remain
dormant in an unfavorable environment and then thrive when growth conditions are optimal
(Clark et al., 2010). Immunosuppression or stressful conditions followed by challenge with C.
septicum, a ubiquitous pathogen, can prompt disease (Clark et al., 2010). Development of
clinical signs and mortalities related to cellulitis commonly result in the affected flock being
treated with antibiotics (Clark et al., 2010). Proper management practices and antibiotic therapy
have proven to reduce the incidence, but does not eliminate the disease.
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Chapter II. Literature Review
Clostridium septicum and other related Clostridial species
Clostridium septicum is a Gram-positive, anaerobic spore forming bacillus that produces
four toxins: alpha-toxin, beta-toxin, gamma-toxin, and delta-toxin (Hatheway 1990) with alphatoxin as the most necrotizing (Tweten et al., 2001). Bacterial toxin production can vary based on
temperature, time, pH, and availability of nutrients (Lalitha et al., 2005). In turkeys, C. septicum
infection is associated with turkey cellulitis (Tellez et al., 2009; Thachil et al., 2013). Areas
affected include the breast, tail, and thigh area where gas produced by the actively replicating
anaerobic bacteria accumulates at the site of infection (Clark et al., 2010). In early observed
cases, C. perfringens Type A was isolated from lesions containing gelatinous fluid under the skin
with the musculature having a dark or greenish appearance (Carr et al., 1995). Other etiologies,
including C. perfringens, have been categorized as a pathogen associated with turkey cellulitis
(Gomis et al., 2001; Gornatti-Churria et al., 2018), however, C. septicum has been proven to be
the principal causative agent (Tellez et al., 2009) and the accumulation of C. septicum alpha
toxin is responsible for accompanying clinical signs (Kennedy et al., 2005).
Following subcutaneous challenge with 0.5, 1, 2, or 3mL of C. perfringens or C. septicum
spore culture, C. septicum spore challenge group had more associated mortalities within 48h in
both 3-week and 7-week old turkeys than the C. perfringens spore challenge group (Thachil et
al., 2010). Gross macroscopic lesions on breast and tail area were observed in both challenge
groups although more severe lesions were detected in the C. septicum challenge group (Thachil
et al., 2010). Hemorrhage and edema was associated with both the dermis and subcutis, with
heterophil infiltration more pronounced in the C. septicum 1mL challenge group and gas
formation identified heavily in the C. septicum 3mL challenge group (Thachil et al., 2010). In
2

turkeys challenged with the higher doses of C. septicum, notable cellular necrosis and
myonecrosis was observed. Within these necrotic regions, there were high numbers of rod
shaped bacteria and low amounts of inflammatory cells (Thachil et al., 2010). There was an
inverse relationship noted between heterophil infiltration and actively replicating bacteria within
the tissue of C. septicum infected turkeys, the group that showed classical cellulitis mortality
response and clinical signs (Thachil et al., 2010). To investigate the incidence and relationship
between C. septicum in broilers and turkeys, 109 C. septicum isolates were recovered from both
turkey and broiler flocks that had a history of dermatitis or cellulitis (Neumann et al., 2009). Out
of the analyzed sequences, only one sequence showed commonality between the broiler and
turkey strain suggesting isolates show specificity (Neumann et al., 2009).
In broiler chickens, gangrenous dermatitis is caused by both C. perfringens and C.
septicum around 6 weeks-of-age (Li et al., 2010). Microscopic evaluation of gangrenous
dermatitis lesions reveal gas and fluid accumulation, necrosis and heterophil infiltration (Li et al.,
2010). Gangrenous dermatitis lesions observed in the breast, abdomen and thigh area were
heavily discolored with emphysema and serosanguinous fluid (Li et al., 2010; Lee et al., 2012).
Intestinal observations reveal severe hemorrhaging thus increasing the permeability of the
intestinal epithelial barrier, allowing potentially allowing for enteric translocation of clostridial
pathogens to the submucosa, and potentially systemically (Li et al., 2010). To identify causative
pathogens associated with gangrenous dermatitis after immunocompromising broilers with an
infectious bursal disease virus vaccination at 14 days, Staphylococcus aureus and C. septicum
isolates, alone or in combination, were administered intramuscularly or subcutaneously to 4week-old broilers (Wilder et al., 2001). Elevated mortality was observed in the C. septicum and
S. aureus challenge groups. However, C. septicum alone was not responsible for dermatitis
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associated lesions in this experiment (Wilder et al., 2001). Li et al., (2010) identified that
gangrenous dermatitis affected broilers had significantly higher C. perfringens serum antibodies
than the non-infected broilers. Interestingly, there was no difference in C. septicum serum
antibodies or Eimeria spp. antibodies between the infected and non-infected group, although
antibody levels were high in both (Li et al., 2010). This indicates that C. perfringens may be the
etiology responsible for gangrenous dermatitis associated lesions and mortalities. In another
study, serum samples were collected from non-affected and gangrenous cellulitis affected
broilers at 35 days-of-age where the non-affected broilers had higher antibody levels to C.
perfringens alpha-toxin and netB than the broilers with clinical signs (Lee et al., 2012). The
authors hypothesized that the non-affected broilers had elevated antibodies levels which
protected them from acquiring the disease (Lee et al., 2012).
In ruminants, blackleg is caused by C. chauvoei, an anaerobic, spore-forming, bacillus
which is generally present in the environment that primarily affects cattle (Useh et al., 2006;
Uzal et al., 2012) and sheep (Useh et al., 2006). It is widely believed that C. chauvoei spores
reside in tissues and germinate at the site of an injury (Useh et al., 2006). The pH and oxygen
availability within damaged muscle continues to change due to replication of C. chauvoei,
creating an environment where the pathogen can efficiently propagate (Useh et al., 2006). C.
chauvoei produces gamma toxins, beta-toxins, hemolysins, and neuraminidases (Useh et al.,
2003). C. septicum has also been isolated from blackleg lesions in cattle but differs from C.
chauvoei based on the presence of edema which is generally not apparent with C. chauvoei
infections (Hatheway, 1990). To prevent blackleg, cattle are vaccinated annually with formalin
inactivated bacterins and if an infection occurs, animals are typically treated with penicillin
(Useh et al., 2006).
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Opportunistically pathogenic clostridial species are nearly ubiquitous in areas where
commercial poultry or livestock are raised. As many or all of these species have a primary niche
of amplification within the gastrointestinal tract, either ingestion of spores or sporulation of
living vegetative cells within the digesta provide a nearly constant source for potential
translocation across the enteric epithelial barrier. When these spores, perhaps carried by the
circulation, are present in damaged tissues with relative anoxia, they may then have the potential
to germinate, replicate, and generate local toxin-associated necrosis, thereby increasing the
ability of these organisms to anaerobically continue to grow. These exotoxins, such as alpha
toxin produced by C. septicum, can also be responsible for initial lesions and ultimately mortality
related to localized tissue diseases.
Clostridium septicum Pathogenesis
As described above, turkey cellulitis is caused by the accumulation of Clostridia,
specifically C. septicum, in lesions leading to edema and inflammation (Clark et al.,
2010). Lesions containing fluid and gas caused by C. perfringens and C. septicum are often
similar, but mortality is more frequent in C. septicum infected turkeys (Thachil et al., 2010).
Pathogens can enter circulation by translocating through the intestinal barrier, through broken
skin or lesions, or by oral inoculation followed by subsequent physical trauma or gut leakage
(Clark et al., 2010). With little known about the mechanisms of this disease, isolation and
identification of the causative agent was imperative to further understand the pathogen most
commonly associated with turkey cellulitis. In 2009, C. septicum was determined to be the most
common pathogen related to turkey cellulitis in commercially produced turkeys (Tellez et al.,
2009).
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C. septicum alpha-toxin is structurally similar to Aeromonas hydrophila aerolysin
(Ballard et al., 1995) being a pore-forming cytolysin where this specific toxin attaches to
glycosylphosylinositol (GPI) protein receptors (Gordon et al., 1999; Kennedy et al., 2005). This
attachment and pore formation results in cell lysis. Kennedy et al. (2005) determined that the
primary virulent attribute of C. septicum is related to alpha-toxin activation and production. Pore
forming toxins, such as C. septicum alpha toxin, affect the permeability of the host cell
membrane by attaching and creating a pore (Popoff et al., 2014) leading to necrosis or apoptosis
(Bischofberger et al., 2012). Pore size ranges from 1.3-1.6 nm in diameter (Knapp et al., 2009).
Alterations in permeability caused by pore formation disrupt several cellular interactions,
including osmotic pressure and ion regulation within the cytosol. When exposed to certain pore
forming proteins, pores are created in low numbers on the membrane and can be repaired via
calcium dependent mechanisms (Babiychuk et al., 2011). This mechanism has not been
evaluated for C. septicum alpha toxin although the probability of membrane repair occurring
after encounter with pore forming toxins is minimal due to the rapid nature of pore formation
(Bischofberger et al., 2012), such as with C. septicum alpha toxin. Increased pore formation
associated with C. septicum alpha toxin may hinder the cell’s ability to self-repair due to the
accumulation of toxin.
Kennedy et al., (2009) analyzed high mobility group box 1 (HMGB1), a protein that
binds to receptor for advanced glycation end products (RAGE) instigating an inflammatory
cascade that signals necrosis in adjacent cells (Scaffidi et al., 2002), for protein expression within
the nucleus and the cytoplasm to determine if C. septicum alpha toxin induces HMGB1
expression in a target cell. A murine myoblast cell line was used with treatments consisting of a
non-treated control, a group treated with 0.1µg/mL alpha toxin, and a group treated with 1µg/mL
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alpha toxin (Kennedy et al., 2009). Translocation of HMGB1 into the cytoplasm only occurred in
the 1µg/mL treated group indicating that C. septicum alpha toxin at that level initiates necrosis
within cells induced by Ca2+ level changes within the cell (Kennedy et al., 2009). Necrosis
associated with C. septicum infections is due to HMGB1 expression by damaged cells, ionic
changes caused by pore formation, and other regulatory changes within the cell (Kennedy et al.,
2009). Although lethality of C. septicum alpha toxin has been evaluated, the primary route of
transmission or portal of entry for turkey cellulitis is still being investigated.
Outside-In Theory
Clostridium septicum is the primary etiology causing turkey cellulitis (Tellez et al., 2009)
though the portal of entry is not fully understood. This bacterium could potentially enter the host
via puncture wounds or scratches (Clark et al., 2010) suggesting that the pathogen could
potentially enter from the “outside”. In an experiment, day-of-hatch poults were subcutaneously
injected in the breast area with C. septicum supernatant, neat C. septicum culture, or a
conjunction of supernatant and convalescent antiserum (Tellez et al., 2009). Supernatant alone
induced classical cellulitis clinical signs within 2h of inoculation (Tellez et al., 2009). No
mortalities occurred 24h post-inoculation in the C. septicum supernatant only group. Supernatant
with various dilutions of the convalescent antisera did not result in any lesions or mortality.
However, injection with the C. septicum neat culture resulted in 78.5% mortality. Each affected
poult had inflammation of the lungs, heart, and peritoneum similarly to observed cellulitis cases.
Since morbidities, but no mortalities occurred in the supernatant only group, Tellez et al.
suggested that the toxin produced by C. septicum may not be responsible for associated
mortalities. However, subcutaneous challenge with neat C. septicum culture was resulted in high
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mortality which may indicate the bacteria were replicating quickly thus producing high
concentrations of exotoxins.
Thachil et al., (2013) investigated immune response post-vaccination with a C. septicum
bacterin-toxoid oil emulsion vaccine with a subsequent challenge in the breast area in
commercial turkeys. In this study, 24 hours post challenge in the breast area, there was 100%
mortality in the control group (Thachil et al., 2013) providing further evidence that C. septicum
can enter through openings in the skin. Reproduction of disease and mortality via subcutaneous
challenge indicates C. septicum could enter through a puncture or wound, such as observed with
a needle during challenge. In the field, this may be via scratches, abrasions, or cuts on the
animal.
Inside-Out Theory
Clostridial species are ubiquitous; therefore, disease may not be apparent until stress
induces intestinal inflammation ultimately resulting in gut leakage allowing the passage of the
pathogen into circulation (Gornatti-Churria et al., 2018). Once in circulation, cells may proceed
to the site of damage or bruising where replication and toxin production likely occur (Clark et al.,
2010). Braxy in sheep and calves, or inflammation of the abomasum caused by a C. septicum
infection, often results in septicemia and high mortality rates (Songer 1996). Intestinal barrier
failure allows for the propagation of diseases related to C. septicum, such as cellulitis.
Cellulitis has not been successfully recreated with an oral challenge model. An
experiment was conducted to determine the effect of dexamethasone treatment, an
immunosuppressant, on mortality associated with C. perfringens and C. septicum challenge
(Thachil et al., 2014). In this experiment, oral challenge with C. perfringens or C. septicum at
both ~107 and 109 cfu/bird did not cause related mortalities in the control or dexamethasone
8

treated group. However, subcutaneous challenge with low dose of C. perfringens resulted in 0%
mortality in both groups while the high dose caused 42% mortality in the positive control group
and 100% mortality in the dexamethasone treated group (Thachil et al., 2014). A subcutaneous
challenge of the low dose C. septicum resulted in 16% morality in the controls and 83%
mortality in the dexamethasone group (Thachil et al., 2014). The high dose C. septicum
subcutaneous challenge caused 100% mortality in both the control group and dexamethasone
treated group. Dexamethasone treatment in conjunction with the oral challenge had no effect on
mortality (Thachil et al., 2014) providing more evidence for the “outside-in” theory. Disease may
not have been observed in the orally challenged group because these animals were not punctured
while the subcutaneously injected turkeys were subjected to dermal puncture at challenge. A
replicate experiment should be conducted to determine if oral challenge followed by sham
subcutaneous challenge (no organism) induces cellulitis. This would provide more information
for the argument of “outside-in” versus “inside-out”.
Experimental Vaccines
Toxoid vaccinations for various Clostridial diseases in humans (Kotloff et al., 2000) and
livestock (Hammer et al., 2007) have been effective. Blackleg in cattle and ruminant animals
caused by Clostridium chauvoei is controlled frequently with vaccines (Useh et al., 2003). A
variety of toxoid vaccines are administered to prevent blackleg consisting of seven Clostridium
isolates, although C. chauvoei and C. septicum are the two that calves are required to be
vaccinated for (Uzal et al., 2012). C. chauvoei spores within the environment can be ingested,
spread throughout circulation and reside in muscular tissue (Useh et al., 2006.). Once an injury
occurs around where the spores are located, blackleg symptoms and mortality ensue (Useh et al.,
2006). However, a toxoid vaccine that provides optimal protection without antibiotic treatment
9

under commercial conditions has not been discovered for turkey cellulitis. Experimental
vaccinations for turkey cellulitis have included inactivated C. perfringens and C. septicum cells
and toxins alone and in combination (Tellez et al., 2009; Thachil et al., 2012; Thachil et al.,
2013). The antigen can be administered as an inactivated bacterin-toxoid or toxoid which will
stimulate an immune response, specifically antibody production, but not cause infection in the
animal. A C. perfringens and C. septicum toxoid vaccine subcutaneously administered at 6
weeks-of-age significantly reduced mortality and penicillin usage, and significantly increased
serum antibody levels to C. septicum and C. perfringens alpha-toxin in commercial turkeys
(Thachil et al., 2012). The mortality percentage in the nonvaccinated group was 9.4% and 7.4%
in the vaccinated group indicating that the vaccination is providing immune protection and
preventing mortalities related to cellulitis (Thachil et al., 2012). There were 547 packs of
penicillin used over 59 days in the nonvaccinated group compared to 361 packs of penicillin
used over 31 days in the vaccinated group (Thachil et al., 2012). Vaccination reduced penicillin
usage days by 50% over the 22- week period although vaccination did not eliminate the need for
penicillin treatment. Although the C. perfringens and C. septicum toxoid vaccination provided
significant protection, this vaccination alone cannot fully control or eliminate this disease.
Although not proven, the possible mode of action for oil emulsion vaccines may be the
ability of creating a depot effect at the site of injection where the antigen is slowly released and
presented to the immune system (Aucouturier et al., 2001). Thachil et al., (2013) conducted an
experiment utilizing a C. septicum toxoid oil emulsion vaccine. Turkeys were vaccinated with a
1mL dose (1.5g of toxoid) or 2mL dose (3g of toxoid) at 6 weeks-of-age (Thachil et al., 2013). A
group of turkeys were boosted at 14 days post-vaccination. Antibody levels were significantly
different between both vaccinated groups and the control groups at both doses as expected. Two
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field studies were conducted to test the effects of the C. septicum bacterin-toxoid. In field study 1
and 2, turkeys were vaccinated with the 1mL dose at 6 weeks-of-age. Cellulitis associated
mortality was reported at 12.1% for the control group and 10.5% for the vaccinated group. The
vaccinated turkeys had significantly less mortalities reported and were administered penicillin 40
days less than the control. In field study 2, mortality in the control group was 1.68% versus
0.87% for the vaccinated group (Thachil et al., 2013). This indicates that this C. septicum
bacterin-toxoid has protective effects against cellulitis in the field, but does not fully eliminate
the use of antibiotics or mortality occurrence.
A C. septicum bacterin-toxoid vaccine has been evaluated using aluminum hydroxide as
an adjuvant (Tellez et al., 2010). To test the ability of inactivated C. septicum vaccine, 10-weekold turkeys were vaccinated with a formalin inactivated C. septicum bacterin-toxoid with
aluminum hydroxide included as the adjuvant (Tellez et. al, 2009). Vaccinated turkeys had
significantly higher C. septicum antibody levels than the nonvaccinated turkeys (Tellez et al.,
2009). Vaccination with C. septicum bacterin-toxoid induces an immune response regardless of
the adjuvant although protection may vary greatly between the adjuvants used.
Lancto et al. (2014) evaluated the efficacy of a noncytolytic C. septicum alpha toxin to
provide protection against C. septicum challenge. Challenge related mortalities were significantly
lower in the noncytolytic C. septicum alpha toxin group when compared to non-vaccinated
controls and there were numerically fewer mortalities within the C. septicum alpha toxinvaccinated group, although not significant (Lancto et al., 2014). The authors suggested that the
safety concerns and cost to produce the recombinant vaccine are lower than for the bacterintoxoid vaccine and even indicate that a water administration with a vector expressing alpha toxin
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antigen would be a viable vaccine alternative to the bacterin-toxoid preparation (Lanco et.,
2014).
Prevention and Treatment Methods
Antibiotics, including penicillin and lincomycin, and/or iodine are administered in the
drinking water (Lighty et al., 2016) at onset of cellulitis-related mortalities and are provided until
cellulitis lesions and mortalities are absent for at least 72 hours (Clark et al., 2010). Currently,
the only effective treatment for turkey cellulitis is antibiotic therapy. Few alternative treatment
and prevention approaches have been investigated. Dexamethasone, a synthetic glucocorticoid,
causes immunosuppression in turkeys (Huff et al., 2013; Thachil et al., 2014) and increases
intestinal leakage and bacterial translocation to the liver in chickens (Vicuna et al., 2015). It has
also been shown to increase the incidence of turkey cellulitis mortalities (Huff et al., 2013; Huff
et al., 2014) To evaluate the effects of yeast extract in the feed or vitamin D in the drinking water
at reducing the incidence of cellulitis associated with stress, turkeys were administered
dexamethasone intramuscularly in conjunction with yeast extract or vitamin D supplementation
(Huff et al., 2014). No cellulitis-related mortalities occurred in the yeast extract treated group
however, 47% of mortalities in the vitamin D treated group had characteristic cellulitis lesions
(Huff et al., 2014). Administration of yeast extract in the feed at the late stages of production
reduced incidence of cellulitis breakout in a flock although further studies need to be conducted
to determine if yeast extract supplementation can prevent cellulitis in a challenge model.
Direct-fed microbials are probiotics included in the diet that are beneficial to the host
(Lee et al., 2010). The addition of a commercially available direct-fed microbial significantly
reduced the presence of C. perfringens in the ceca and in the feces compared to a non-treated
group (Rahimi et al., 2011). Commercially, for cellulitis prevention, selected Bacillus isolates
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have been included in the diet, although this does not fully avert the disease (Clark et al., 2010).
Periodic inclusion of direct-fed microbial probiotics would provide flocks with beneficial
bacteria that may prevent colonization of potentially harmful bacteria, such as C. septicum.
In 2008, a meeting was held by collaborators in the industry to discuss and assemble
prevention measures for producers to ultimately minimize the risk of disease and mortality
associated with turkey cellulitis (Clark et al., 2010). A few recommendations included
continuous education for farmers and others involved with turkey production, antibiotic
treatment (dose, timing, type), immediate removal of any mortalities, and improved management
practices to reduce the impact of environmental related factors (Clark et al., 2010). In the United
States, many commercial turkey producers continuously reuse litter and the build-up of used
litter is correlated with turkey cellulitis (Clark et al., 2010). In Europe, turkey cellulitis is not an
apparent threat to the turkey industry due to the all-in, all-out type of production systems,
including complete cleanout and disinfection, that has been adopted (Clark et al., 2010). Reusing
litter in the US, especially after a flock with high incidence of cellulitis, possibly subjects
subsequent flocks to a challenge with the pathogenic organism that is present in the environment.
Similarly, to the experimental breast area challenge, the flocks raised on reused litter may be
naturally challenged through cuts or scratches on the skin. Complete removal of used litter and
replacement with fresh litter may be necessary to reduce disease related to litter quality. A study
conducted comparing control farms with high incidence farms determined that elevated soil pH,
high humidity levels within the barn, and the presence of a litter composting pile 200 feet from
the barn increased the occurrence of turkey cellulitis (APHIS, 2012). Barn management
practices can be improved, but these practices are difficult to implement across the United States.
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Conclusion
Clostridia are ubiquitous and are able to reside in the environment for extended periods of
time. Commercial turkeys are frequently exposed to C. septicum, the pathogenic etiology linked
to turkey cellultis, most frequently by injury to the dermis where this anaerobic, highly toxigenic
rod replicates rapidly at the site of entry. In livestock, clostridial-related diseases can be
prevented with vaccines and controlled with antibiotics. However, numerous vaccinations are
difficult for commercial turkey producers because of the large labor cost attributed to handling
each turkey. Experimental cellulitis vaccines have been evaluated with moderate success due to
the need of intermittent treatment with antibiotics even after vaccination. Evaluating the efficacy
of multiple adjuvants with a C. septicum bacterin-toxoid can provide implications for which
vaccine to use in the field.
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ABSTRACT
Alpha-toxigenic Clostridium septicum (CS), the primary etiology of turkey cellulitis, results in
devastating mortality. Various experimental vaccines have been evaluated to prevent this disease
with variable but partial success. The ability of a CS bacterin-toxoid, in conjunction with
adjuvants such as aluminum hydroxide, mannoslyated chitosan, or a water-in-oil Seppic
Montanide 71 R VG adjuvant (OE) to induce immunity was evaluated in a 7-week study
(Experiment 1). Poults (20/group) were vaccinated on day-of-hatch, boosted at 5 weeks-of-age
and compared to unvaccinated controls. Antibody levels were determined by ELISA for all
experiments. In experiment 1, initial vaccination with the OE resulted in significantly (P<0.05)
higher antibody levels at 5 weeks-of-age, and at 7 weeks-of-age OE resulted in numerically
increased antibody levels compared to all vaccinated groups. Efficacy of the OE vaccine was
then evaluated in two field trials (Experiments 2 and 3) with treatments including a nonvaccinated control group and a vaccinated group (~50% each). Non-vaccinates were marked by
dewclaw removal at the hatchery and were comingled during growout (Experiments 2 and 3).
Experiment 2 consisted of 3 houses: House 1 (HS1), House 2 (HS2), and House 3 (HS3).
Mortality associated with cellulitis was recorded once the first case was observed. Blood samples
were obtained at 8, 12, and 16 weeks-of-age. Antibody levels (S/P ratio) in vaccinated groups for
weeks 12 and 16 were significantly higher (P<0.05) than the control groups for all 3 houses. In
HS1 and HS2, low CS-associated mortality was observed and there was no significant difference
in mortality/total (%) between control and vaccinated group. In HS3, control mortality (%) was
significantly (P<0.001) higher than mortality in vaccinated turkeys. Experiment 3 consisted of 6
farms with 1-4 houses/farm. Vaccination significantly (P<0.05) reduced CS-related mortalities as
compared to controls in 5 of 6 farms in experiment 3 and antibody titers were significantly
20

(P<0.05) higher in vaccinated turkeys at 12 and 16 weeks for all 6 farms. Based on these results,
W/O emulsion vaccines, such as this alpha-toxin bacterin-toxiod with Montanide 71 R VG
adjuvant, can be used to increase antibody titers and may reduce related mortalities in the field.
Keywords: oil-emulsion vaccine; turkey cellulitis; Clostridium septicum; alpha-toxin; antibody

titer
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INTRODUCTION
Turkey cellulitis or clostridial dermatitis is primarily caused by Clostridium septicum (Tellez et
al., 2009), a Gram positive, anaerobic rod primarily affecting commercial turkey flocks later in
production (Clark et al., 2010). The incidence of cellulitis is costly due to the increase in
production expenses at the onset of disease (Lighty et al., 2016). Cellulitis lesions occur in areas
such as the breast region where discoloration, edema and gas accumulation are commonly
observed (Clark et al., 2010). Pathogens, such as C. perfringens, have been affiliated with
cellulitis, however C. septicum alpha toxin is the most virulent exotoxin responsible for necrosis
associated with C. septicum infections (Kennedy et al., 2005). Subcutaneous challenge models
(Tellez et al., 2009; Thachil et al., 2010; Thachil et al., 2014) have been more effective than oral
challenge models (Thachil et al., 2014) possibly indicating that C. septicum primarily enters the
animal through scratches or punctures of the skin rather than by oral inoculation, although the
possibility of systemic seeding due to enteric translocation has not been eliminated. C. septicum
is a ubiquitous pathogen which makes this disease difficult to prevent or control under
commercial conditions (Clark et al., 2010). Antibiotic therapy can effectively treat this disease;
however, a prevention method is needed to reduce the use of antibiotics. Experimental vaccines
have been investigated for cellulitis, such as a C. perfringens and C. septicum bacterin-toxoid
(Thachil et al., 2012), a recombinant C. septicum alpha toxin peptide vaccine (Lancto et al.,
2014), and C. septicum bacterin-toxoids (Tellez et al., 2009; Thachil et al., 2013). Vaccination
with a C. septicum bacterin-toxoid mineral oil vaccine reduced antibiotic usage and associated
mortalities compared to non-vaccinated controls (Thachil et al., 2013). It has been hypothesized
that water-in-oil emulsion vaccines create a depot or repository effect which stimulates and
provides long term interaction with the immune system and antigen, thus elevating the overall
22

immune response (Aucouturier et al., 2001). Water-in-oil emulsion vaccines consist of a
liquid/antigenic part and an oil part which are homogenized to achieve a target droplet size and
uniformity. Aluminum hydroxide is commonly used as an adjuvant and may be an effective by
creating a depot effect at the site of vaccination (He et al., 2015). Mannosylated chitosan has
been combined with multiple antigens to enhance the immune response (Hargis et al., 2015). The
purpose of these experiments was to evaluate and compare the efficacy of multiple adjuvants
with a C. septicum bacterin-toxoid antigen to induce an immune response under laboratory
conditions and then test the most efficacious vaccine under commercial conditions.
MATERIALS AND METHODS
Bacterial isolates
Isolation, identification, and culture of isolates used in these experiments has been previously
described (Tellez et al., 2009). Briefly, two Clostridium septicum (CS) isolates from fluid
emphysematous lesions of cellulitis in commercial turkeys that died acutely were purified and
identified using commercial anaerobic identification panels (RapID ANA II anaerobic
identification panels, Remel Inc., Lenexa, KS). From this, an experimental bacterin/toxoid was
produced from two CS isolates that were capable of causing lesions consistent with turkey
cellulitis and was recovered from induced lesions, as described. The bacterin was produced from
an anaerobic 18h tryptic soy broth and sodium thioglycollate (0.5%) culture of CS, inactivated
by the addition of formaldehyde (Fisher, Waltham, MA) to achieve a final concentration of
0.25%. Inactivation was timed to allow accumulation of toxin and 108 cells/mL (24- hr
incubation) as verified by quantitative enumeration and hemolysin titration (Hang’ombe et al.,
2005).
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CS bacterin-toxoid Vaccine Preparation
Adjuvants were combined with the CS bacterin-toxoid as follows. Aluminum hydroxide (Rugby
Labs, Duluth, GA.) was included as an adjuvant at 12% (v/v) (Experiment 1). Mannosylated
chitosan (Hargis et al., 2015) was included at a 2:1 ratio with the bacterin-toxioid (Experiment 1
and 2). A commercial water-in-oil adjuvant (Seppic Montanide 71R VG) was included at 70%,
per manufacturer’s instructions (Experiment 1, 2 and 3). For the OE vaccine, the CS bacterintoxoid was added to oil component and homogenized over a 45 second duration at low speed
using a PRO 200 homogenizer, (PRO Scientific Inc., Oxford, CT). Following addition of
antigen, oil emulsion was homogenized for 5 minutes. Emulsion stability decreased when
homogenization time continued longer than 5 minutes. Droplets size for oil emulsion vaccine
ranged from 1-2 μm. Stability of emulsion was evaluated and verified to be stable at 4C for at
least 30 days. Sterility was verified by spread plating 100µl of prepared vaccine on sheep blood
agar and incubating aerobically and anaerobically at 37C for 18h.
Indirect Enzyme-Linked Immunosorbent Assay (ELISA)
The indirect enzyme-linked immunosorbent assay (ELISA) used for measuring relative antibody
levels against the potential CS etiology has been previously described (Tellez et al., 2009). This
assay was used to show that vaccinated turkeys had increased levels of antibodies to CS or that
turkeys with higher levels of antibodies were less likely to contract cellulitis. The assay was
performed similarly to previously described methods (Roberts et al., 1987; Ameiss et al., 2004;
Hang’ombe et al., 2005). Absorbance was read at 450 nm using a commercial microplate reader
(BioTek MQX200, BioTek Instruments Inc., Winooski, VT.). The absorbance obtained for the
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positive control, negative control, and experimental samples was used to calculate the sample to
positive control ratios (S/P ratios) (Brown et al., 1991; Davies et al., 2003).
EXPERIMENTAL DESIGN
Laboratory Trial
Experiment 1 was conducted comparing the effects of adjuvants including aluminum hydroxide,
mannosylated chitosan, or commercial water-in-oil adjuvant, Seppic Montanide 71R VG with
the CS bacterin-toxoid. 100 day-of-hatch commercial cross poults were obtained from a local
hatchery and transferred to the University of Arkansas JKS Poultry Health Laboratory
(Fayetteville, AR). Poults (n=20 per treatment) were randomly assigned to one of five treatment
groups and then individually neck tagged according to treatment. Treatment groups were
subcutaneously (neck) vaccinated with respective candidate vaccines on day-of-hatch (prime)
with 0.25mL and boosted at 5 weeks-of-age with 0.5mL. Treatment groups included 1) nonvaccinated control, 2) alum prime + oil emulsion (OE) boost, 3) mannosylated chitosan (MCA)
prime + MCA boost, 4) MCA prime + alum boost, 5) and an oil emulsion prime + oil emulsion
group boost. Turkeys were comingled and provided feed and water ad libitum for the 7-week
duration of the experiment. Serum samples were obtained at 2, 5 and 7 weeks-of-age. No
cellulitis-associated lesions or mortalities were observed in this experiment. Vaccine injection
site lesions were scored post-mortem by a licensed veterinarian as a 0 (not present), 1 (detectable
but insignificant), 2 (moderate), and 3 (clinically meaningful lesions).
Field Trial 1
Experiment 2 included 3 houses (HS) with each having a non-vaccinated control and vaccinated
group. Control turkeys were distinguished by the removal of the dewclaw and were comingled
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with vaccinated turkeys. Vaccinated turkeys were primed at day-of-hatch with a CS
bacterin/toxoid MCA vaccine and subcutaneously boosted at 8 weeks-of-age with the CS
bacterin/toxoid oil emulsion vaccine (0.5mL). Allocation treatments was as follows: HS 1
consisted of 5800 control turkeys and 4800 vaccinated turkeys, HS 2 consisted of 4800 control
turkeys and 5000 vaccinated turkeys, and HS 3 with 4100 control turkeys and 5100 vaccinated
turkeys. Mortality was calculated based on percent of each group. Blood samples were obtained
from 20 per treatment per house at 8, 12, and 16 weeks-of-age. Mortality estimates were reported
from 13-16 weeks-of-age. Antibiotic treatment was administered when cellulitis mortalities were
observed, however, the duration of antibiotic therapy was not provided in this trial.
Field Trial 2
Experiment 3 consisted of 6 farms with 1-4 houses per farm as described in Table 4. Nonvaccinated control and vaccinated group were allocated evenly. Control turkeys were
distinguished by the removal of the dewclaw and were comingled with vaccinated turkeys.
Turkeys were subcutaneously vaccinated (0.5mL) at 8 weeks-of-age with CS toxoid oil emulsion
vaccine. Blood samples were obtained from 10 per treatment per house at 8, 12, and 16-20
weeks-of-age based on collection date determined by producer. Mortality estimates were
reported from 13-21 weeks-of-age. Similar to experiment 2, antibiotic therapy was administered
at onset of disease and duration of treatment was recorded (Table 5).
Statistical Analysis
All data were subjected to Analysis of Variance as a completely randomized design using the
General Linear Models procedure of SAS (SAS Institute, 2002). Antibody response data is
expressed as mean ± standard error, in all experiments. Significant differences among means
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were determined by using Tukey’s multiple-range test (Experiment 1) at P < 0.05. Chi-squared
test of independence (Zar, 1984) was used to determine significant (P < 0.05) differences for
mortality.
RESULTS AND DISCUSSION
Toxoid vaccines have successfully prevented Clostridial diseases, such as blackleg in
ruminants (Useh et al., 2006; Uzal et al., 2012). Vaccines for turkey cellulitis including a C.
septicum bacterin-toxiod combined with an aluminum hydroxide adjuvant (Tellez et al., 2009), a
recombinant C. septicum alpha toxin peptide (Lancto et al., 2014) and both a C. septicum
bacterin-toxiod and C. septicum and C. perfringens bacterin-toxoid mixed with an oil emulsion
adjuvant (Thachil et al., 2012; Thachil et al., 2013) have been evaluated and proven to have some
protective effects.
In experiment 1, at 2 weeks post-prime, a group vaccinated day-of-hatch with MCA CS
bacterin-toxoid had significantly (P<0.05) higher antibody levels than the non-vaccinated
control, but was not statistically different than vaccinated groups. At 5 weeks post-prime, turkeys
vaccinated on day-of-hatch with the CS oil emulsion vaccine had significantly (P<0.05) higher
antibody levels than all groups. By 7 weeks-of-age, all vaccinated groups had markedly (P<0.05)
higher antibody levels than the control however there was no statistical difference between
vaccinated groups. CS oil emulsion prime + CS oil emulsion boost group resulted in the most
elevated immune response compared to all treatment groups followed by the Alum prime + CS
oil emulsion boost group (Table 1). We identified that prime and boost vaccination with the C.
septicum bacterin-toxoid oil emulsion vaccine elicits a more robust immune response than the
alternatives evaluated (Table 1). This, in part, may be due to the fact that oil emulsion vaccines
provide long term protection against the antigenic portion included in a vaccine due to the
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accumulation of a depot at the injection site (Aucouturier et al., 2001). Antigen should be
released slowly from this repository over an extended period thus increasing encounter of
antigen with antigen presenting cells. Continuous interaction between antigen and antigen
presenting cells provides constant stimulation of the immune system and subsequent antibody
production (Awate et al., 2014). Vaccine injection sites were evaluated post mortem to determine
if there were any lesions associated with the adjuvants tested in experiment 1. MCA prime +
MCA boost and MCA prime + alum boost groups had no observed lesions at vaccine injection
site. However, in the both oil emulsion vaccine groups there were lesions present at the injection
site (Table 2). Injection site lesions associated with oil emulsion vaccination were consistent
with lesions induced by commercial oil emulsion vaccines (data not shown). There were no
cellulitis related morbidities or mortalities in experiment 1 (Table 2).
In experiment 2, there was no difference in titer between the control and vaccinated
group at 8 weeks post-prime with the CS MCA vaccine. However, at 12 and 16 weeks-of-age (4
and 8 weeks post-boost with the CS oil emulsion vaccine), the vaccinated group had significantly
(P<0.05) higher antibody levels than the control group in all three houses (Table 3). Vaccinated
turkeys in experiment 2 were primed with the C. septicum MCA vaccine which may have
stimulated a primary immune response. The prime vaccination could explain the higher antibody
levels that were observed in the vaccinated group for this experiment. Mortality was reported
from 13-16 weeks-of-age although the results are complicated due to the intermittent use of
antibiotics. In HS 1 and 2, CS-related mortalities were low in both groups and there was no
mortality differences observed between the control and vaccinated group. However, in HS 3,
there was a significant (P<0.001) reduction in cellulitis related mortalities in the vaccinated
group (Table 3). The significantly lower mortality observed in the vaccinated treatment group
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may be a result a higher bacterial challenge being present in this house, thus the vaccinated
group had a sufficient immune response to the C. septicum bacterin-toxoid oil emulsion vaccine
and were protected whereas the non-vaccinated controls were naïve to the antigen.
Experiment 3 consisted of 6 farms with 1-4 houses per farm. At vaccination (8 weeks-ofage), there was no antibody level differences between control and vaccinated groups. At 12
weeks-of-age (4 weeks post vaccination), vaccinated groups had a significantly (P<0.05) more
robust immune response than the control groups. Vaccinated group antibody titers were
significantly (P<0.05) higher than control groups at 16-20 weeks-of-age (Table 4). Mortality was
reported between 13-21 weeks-of-age. Cellulitis-associated mortalities were significantly
(P<0.05) lower in vaccinated groups than control groups in 5 of the 6 houses. There were 24%
less cellulitis-related mortalities in the vaccinated groups in experiment 3 (Table 5). Similar to
experiment 2, if antibiotic treatment was required, both the control and the vaccinated groups
were subjected to the treatment. Previously, Thachil et al., (2013) evaluated a CS bacterin-toxoid
oil emulsion vaccine and observed a significant reduction in antibiotic usage and cellulitis
mortalities in the vaccinated group. Vaccinate antibody titers were elevated and had complete
protection against C. septicum challenge while non-vaccinates had low antibody levels with
100% mortality 24 hours post challenge (Thachil et al., 2013). This indicates that an oil emulsion
vaccine for cellulitis can protect against experimental subcutaneous challenge (Thachil et al.,
2013).
These data show that the C. septicum bacterin-toxoid oil emulsion vaccine used in these
experiments elicits robust immune response and may reduce the incidence of cellulitis related
mortalities. Vaccine efficacy without antibiotic treatment under commercial conditions is
currently unknown. Further studies need to be conducted to determine effectiveness of a
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subsequent boost vaccination in a field study, protective ability of this C. septicum bacterintoxoid oil emulsion vaccine against experimental C. septicum challenge, and evaluation of
vaccine efficacy without antibiotic treatment.
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List of Tables
Table 1. Antibody response to Clostridium septicum following vaccination with various CS
bacterin-toxoid/adjuvant combinations (Experiment 1)
2 weeks postprime

5 weeks postprime, preboost

7 weeks postprime, 2 weeks
post-boost

Mortality*,1

Control

0.14 ± 0.02b

0.44 ± 0.04b

0.34 ± 0.06 b

1/12 (8.33%)

Alum + OE

0.16 ± 0.02 ab

0.51 ± 0.06 b

1.48 ± 0.13a

0/15 (0%)

MCA + MCA

0.16 ± 0.03 ab

0.55 ± 0.06 b

1.30 ± 0.14 a

1/17 (5.89%)

MCA + Alum

0.31 ± 0.05 a

0.35 ± 0.06 b

1.25 ± 0.13 a

1/17 (5.89%)

OE + OE

0.26 ± 0.06 ab

1.06 ± 0.14 a

1.63 ± 0.17 a

1/18 (5.56%)

a, b

Indicates significant differences (P < 0.05) between treatment groups by age
Turkeys were primed on day-of-hatch with 0.25mL and boosted at 5 weeks-of-age with respective vaccine
1 Several neck tags were lost in each group. Mortality was calculated on the basis of the number of birds
with retained neck tags at the end of the experiment
*No cellulitis lesions observed and no challenge was administered in this experiment

Table 2. Localized reactions at vaccine injection site evaluated post-mortem at 7 weeks-of-age
(Experiment 1)
Treatment
Non-vaccinated Control
Alum + OE
MCA + MCA
MCA + Alum
OE + OE

0
12/12 (100%)
5/15 (33%)
17/17 (100%)
17/17 (100%)
6/18 (33.3%)

1
0/12 (0%)
9/15 (60%)
0/17 (0%)
0/17(0%)
9/18 (50%)

Score
2
0/12
1/15 (6.7%)
0/17 (0%)
0/17 (0%)
3/18 (16.7%)

3
0/12 (0%)
0/15 (0%)
0/17 (0%)
0/17 (0%)
0/18 (0%)

Turkeys were comingled for the duration of the trial. Injection site lesions were not evaluated for turkeys which lost
neck tags
Scoring: 0 (not present), 1 (detectable but insignificant), 2 (moderate), and 3 (clinically meaningful lesions)
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Table 3. Cellulitis-related mortalities and antibody response Clostridium septicum at 8, 12, and
16 weeks post-vaccination (Experiment 2)

HS 1 Control
HS 1 Vaccinated
HS 2 Control
HS 2 Vaccinated
HS 3 Control
HS 3 Vaccinated

8 weeks postprime, preboost
0.25 ± 0.01 a
0.30 ± 0.02 a
0.25 ± 0.02 a
0.29 ± 0.02 a
0.24 ± 0.02 a
0.28 ± 0.06a

12 weeks postprime, 4 weeks
post-boost
0.39 ± 0.05 b
2.16 ± 0.16 a
0.46 ± 0.09 b
1.71 ± 0.13 a
0.32 ± 0.03 b
1.60 ± 0.11a

a, b

16 weeks postprime, 8 weeks
post-boost
0.37 ± 0.02 b
1.57 ± 0.08 a
0.41 ± 0.07 b
2.40 ± 0.15 a
0.56 ± 0.18 b
2.12 ± 0.15a

Late mortality
associated with
cellulitis
81
80
70
80
148
78*

Indicates significant differences (P < 0.05) between control and treatment group by house
Vaccinated turkeys were primed with CS bacterin-toxoid MCA vaccine day-of-hatch and boosted (0.5mL) with CS
bacterin-toxoid oil emulsion vaccine at 8 weeks-of-age
n=20/group
*Indicates significant difference (P < 0.001) between control and vaccinated group by house
Mortality reported between 13 and 16 weeks-of-age
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Table 4. Antibody response at 8, 12, and 16-20 weeks-of-age (Experiment 3)

Farm 1

n/farm (# of houses) †
13608 (2)

Farm 2

21600 (4)

Farm 3

21600 (4)

Farm 4

6792 (1)

Farm 5

36288 (3)

Farm 6

18774 (3)
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a, b

Treatment
Control
Vaccinated
Control
Vaccinated
Control
Vaccinated
Control
Vaccinated
Control
Vaccinated
Control
Vaccinated

Antibody Response (S/P) ratio
8 weeks
12 weeks
16-20 weeks*
0.43 ± 0.02 a
0.56 ± 0.03 b
1.28 ± 0.02 b
0.40 ± 0.02 a
0.88 ± 0.07 a
2.01 ± 0.16 a
a
b
0.31 ± 0.01
0.81 ± 0.03
1.01 ± 0.04 b
0.30 ± 0.01 a
1.29 ± 0.10 a
1.91 ± 0.12 a
0.37 ± 0.02 a
0.64 ± 0.02 b
1.08 ± 0.04 b
0.38 ± 0.01 a
1.02 ± 0.06 a
2.16 ± 0.09 a
0.61 ± 0.04 a
0.77 ± 0.06 b
1.12 ± 0.11 b
0.63 ± 0.04 a
1.15 ± 0.15 a
1.57 ± 0.15 a
0.51 ± 0.03 a
0.66 ± 0.03 b
0.98 ± 0.06 b
0.51 ± 0.01 a
0.99 ± 0.06 a
1.39 ± 0.13 a
0.53 ± 0.02 a
0.92 ± 0.05 a
1.38 ± 0.08 a
0.52 ± 0.02 a
1.19 ± 0.05 b
1.90 ± 0.12 b

Indicates significant differences (P < 0.05) between control and treatment group by farm
*Collection date determined by producer
Vaccinated turkeys were subcutaneously vaccinated (0.5mL) with CS bacterin-toxoid oil emulsion vaccine at 8 weeks-of-age
n=10/group
†
n/treatment was allocated evenly between control and vaccinated group for all houses

Table 5. Late cellulitis-associated mortalities (Experiment 3)

Farm 1
Farm 2
Farm 3
Farm 4
Farm 5
Farm 6
Exp 2 total†

Control
Mortality

Vaccinated
Mortality

Total Late
Mortality

Total Late
Mortality as %
of Farm

Antibiotic
Treatment (# of
days)

131 (76%)
10 (24%)*
19 (86%)
160 (71%)
749 (59%)
266 (63%)
1335 (62%)

42 (24%)*
31(76%)
3 (14%)*
64 (29%)*
514 (41%)*
158 (37%)*
812 (38%)

173
41
22
224
1263
424
2147

1.27%
0.19%
0.10%
3.30%
3.48%
2.26%
1.81%

42
14
0
35
42
35
-

*Indicates significant differences (P < 0.05) between control and treatment group by farm
(%) indicative of a percent of total late mortalities
†
Statistical analysis not conducted due to variability between farms
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Chapter IV. Conclusion
C. septicum alpha-toxin is the primary virulent toxin responsible for inducing cellulitis.
Preventative measures, such as improved flock management and direct-fed microbials, can
reduce the risk of disease, however antibiotic therapy is still required. An effective vaccine could
provide immune protection for flocks if vaccinated prior to infection. Oil emulsion vaccines
induce long term robust immunity to the antigenic portion of the vaccine, such as the C. septicum
bacterin-toxoid evaluated in these experiments. Although booster vaccination under field
conditions are not ideal, it may be necessary to prevent turkey cellulitis related mortalities
without antibiotic treatment.
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